Rakuten Medical Announces New Name Alluminox for its Proprietary Technology Platform
SAN DIEGO, March 7, 2022 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) has elected to discontinue use of the name “Illuminox,” and to start using a new, evolved name Alluminox for our proprietary, anti-cancer, photoimmunotherapy technology platform , which is comprised of drug, medical device, and other related technologies. This name change will take effect globally from April 1, 2022.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its Illumino platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Illuminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has offices in 5 countries, including the United Stateswhere it is headquartered, Japan, the Netherlands, Taiwan and Switzerland.
https://empactstrong.com/...-for-its-proprietary-technology-platform/ |